Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo
- 31 October 1999
- Vol. 54 (4), 662-669
- https://doi.org/10.1016/s0090-4295(99)00232-0
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trialUrology, 1998
- Long-Term Effects of Finasteride in Patients with Benign Prostatic Hyperplasia: A Double-Blind, Placebo-Controlled, Multicenter StudyUrology, 1998
- The so-called “placebo effect” in benign prostatic hyperplasia treatment trials represents partially a conditional regression to the mean induced by censoringUrology, 1998
- The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic HyperplasiaNew England Journal of Medicine, 1998
- Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trialsUrology, 1996
- The hytrin community assessment trial study: A one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasiaUrology, 1996
- Can finasteride reverse the progress of benign prostatic hyperplasia? a two-year placebo-controlled studyUrology, 1995
- Natural history of prostatism: Impact of urinary symptoms on quality of life in 2115 randomly selected community menUrology, 1994
- The American Urological Association Symptom Index for Benign Prostatic HyperplasiaJournal of Urology, 1992
- The Effect of Finasteride in Men with Benign Prostatic HyperplasiaNew England Journal of Medicine, 1992